Dexamethasone after early-life seizures attenuates increased susceptibility to seizures, seizure-induced microglia activation and neuronal injury later in life

•KA-SZ in P25 rat increased seizure severity, injury, and activated microglia at P39.•Short course (2-day) dexamethasone after KA-SZ decreased acute microglia activation.•Post-SZ dexamethasone decreased severity of seizures provoked at P39.•Post-SE dexamethasone decreased second SZ-induced microglia...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience letters 2020-05, Vol.728, p.134953-134953, Article 134953
Hauptverfasser: Fox, Patrick, Mithal, Divakar S., Somogyi, Jason R., Vien, Albert C., Sanchez, Russell M., Koh, Sookyong
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•KA-SZ in P25 rat increased seizure severity, injury, and activated microglia at P39.•Short course (2-day) dexamethasone after KA-SZ decreased acute microglia activation.•Post-SZ dexamethasone decreased severity of seizures provoked at P39.•Post-SE dexamethasone decreased second SZ-induced microglia activation and injury.•Prolonged dexamethasone (1 week) caused weight loss and mortality regardless of SZ. Chronic epilepsy can begin with isolated early-life prolonged seizures followed by remission and the re-emergence of seizures later in life. Seizures are known to trigger a neuroinflammatory response to promote neuronal damage and increase the risk of epilepsy. We examined whether post-seizure anti-inflammatory treatment with dexamethasone after early-life seizures could decrease future seizure susceptibility and ameliorate heightened microglia activation and cell injury in response to later-life seizures. Using a “two-hit” model, early-life seizures (SZ) were induced in rats on postnatal day (P) 25 by systemic kainic acid (KA) injection followed by later-life KA at P39. P25 animals were administered anti-inflammatory drugs for 2 or 7 days after first KA exposure to inhibit seizure-induced inflammation. Hippocampal microglial activation was measured after first or second KA treatments to assay neuroinflammation, and the latency and severity of seizures to the second KA treatment were measured to determine seizure susceptibility. In situ end labeling for DNA fragmentation was used to compare KA-induced neuronal injury between treatment groups after the second KA administration. KA-SZ at P25 caused marked microglia activation within 48 hours. At P39, KA-SZ in rats without prior seizures caused a modest (2-fold) increase in microglia assayed 72 hours after KA. In contrast, microglia were markedly activated (5-fold) in response to a second KA-SZ at P39. Short-course (2 days) dexamethasone significantly decreased seizure-induced microglia activation at P25, and ameliorated the exaggerated microglia activation, cell injury, and heightened susceptibility to second-hit seizures. Although short-course dexamethasone was effective, longer term (7 days) administration of dexamethasone resulted in decreased weight gain and increased mortality in animals with or without KA-induced seizures. These data indicated that acute short-term steroid therapy after SZ could inhibit seizure-induced microglia activation and decrease the long-term damaging effects of early-life SZ. T
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2020.134953